Loading
Life sciences · Review
Epigenomics · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The clinical validation of mRNA-based COVID-19 vaccines in 2020-2021 accelerated the development of synthetic messenger RNA as a precision therapeutic platform beyond infectious disease prevention. Unlike gene therapy approaches that permanently modify genomic DNA, synthetic mRNA enables transient protein expression through programmable molecular engineering. This narrative review examines therapeutic applications of engineered mRNA, emphasizing its epigenomic potential. It discusses key engineering strategies, including nucleoside modifications, codon optimization, untranslated region engineering, cap chemistry, and advances in lipid nanoparticle and alternative delivery systems. Six therapeutic domains are explored: cancer immunotherapy, cardiac regeneration, monogenic diseases, genome and epigenome editing, autoimmune disease, and somatic cell reprogramming. Particular attention is given to mRNA-mediated replacement of chromatin regulators, dCas9-based epigenome editing, epigenetically derived tumor antigens, and transcription-factor-driven cellular reprogramming. The review distinguishes chemical nucleoside modifications from endogenous epitranscriptomic regulation and examines the differences between transient protein expression, heritable but reversible chromatin changes, and permanent genomic modifications. Clinical evidence, discontinued programs, and preclinical developments are critically evaluated. Despite promising advances, major challenges remain regarding delivery specificity, durability, safety, and clinical translation. Overall, synthetic mRNA represents an emerging platform for molecular and epigenetic therapeutic reprogramming beyond vaccination.